{"analyses":[{"groupDescription":"one-side log rank test comparing median PFS between treatment arms","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.25","statisticalComment":"one-side log rank test","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"3.8","value":"2.9"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"5.6","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"description":"From initiation of treatment with nivolumab until the time of disease progression, time measured in months. Kaplan-Meier analysis performed to estimate the median progression-free survival with a 90% confidence interval.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants enrolled into Arm I received single agent Nivolumab.","id":"OG000","title":"Part B Arm I (Nivolumab)"},{"description":"Participants enrolled into Arm II received combination Nivolumab plus Ipilimumab.","id":"OG001","title":"Part B Arm II (Nivolumab, Ipilimumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time period from the date of randomization to the date of PD or death whichever occurred first, assessed up to 2 years","title":"Progression-free Survival (PFS) (Part B)","type":"PRIMARY","unitOfMeasure":"months"}